The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea

被引:9
作者
Choi, Hoon [1 ]
Chung, Hong [2 ]
Park, Jae Young [1 ]
Lee, Jeong Gu [1 ]
Bae, Jae Hyun [1 ]
机构
[1] Korea Univ, Ansan Hosp, Coll Med, Dept Urol, Ansan, South Korea
[2] Konkuk Univ Hosp, Dept Urol, Chungju, South Korea
关键词
Androgen Deprivation Therapy; Prostate Neoplasms; Prostate Volume; URINARY-TRACT SYMPTOMS; HORMONE AGONISTS; VOLUME REDUCTION; HYPERPLASIA; MEN; BRACHYTHERAPY; ASSOCIATION; INHIBITION; CARCINOMA; RECEPTOR;
D O I
10.5213/inj.1632628.314
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The goal of this study is to investigate the effects of androgen deprivation therapy (ADT) on total prostate volume and lower urinary tract symptoms (LUTS). Methods: Between January 2007 and June 2014, 110 patients who received androgen deprivation treatment were enrolled in this retrospective study. Clinical parameters and urodynamic parameters along with changes at follow-up were analyzed. Factors such as reduction in prostate volume, changes in LUTS, and prostate volume tertiles were compared 1 year after ADT. Results: After ADT, the total International Prostate Symptom Score (IPSS) score decreased from 17.45 to 12.21 and the IPSS voiding subscore decreased from 9.16 to 6.24. Maximal uroflow rate increased from 8.62 to 11.50 mL/sec and residual urine also reduced significantly by 29.34 mL. Change in prostate size was more prominent (-51.14%) in the patients with less than 1 year of ADT (n=21) than those who had more than 1 year of treatment (n = 89, -44.12%). The decrease in the IPSS voiding subscore was greater within 1 year of ADT than after 1 year of treatment (-4.10 vs. -2.65). The differences were more significant in the 30-50 g group (n = 59) and > 50 g group (n =11) than the <30 g group (n = 40) of the IPSS voiding subscore improvement (-3.76, -4.91 vs. -2.10), and maximal uroflow rate improvement (2.78, 2.90 vs 1.49). Conclusion: ADT resulted in statistically significant clinical improvement in terms of prostate volume, urodynamic parameters, and LUTS for patients with prostate cancer when analyzed by ADT duration and prostate volume.
引用
收藏
页码:342 / 348
页数:7
相关论文
共 26 条
[1]   Degarelix versus Goserelin ( plus Antiandrogen Flare Protection) in the Relief of Lower Urinary Tract Symptoms Secondary to Prostate Cancer: Results from a Phase IIIb Study (NCT00831233) [J].
Anderson, John ;
Al-Ali, Ghandi ;
Wirth, Manfred ;
Benejam Gual, Joan ;
Gomez Veiga, Francisco ;
Colli, Enrico ;
van der Meulen, Egbert ;
Persson, Bo-Eric .
UROLOGIA INTERNATIONALIS, 2013, 90 (03) :321-328
[2]   Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide [J].
Axcrona, Karol ;
Aaltomaa, Sirpa ;
da Silva, Carlos Martins ;
Ozen, Haluk ;
Damber, Jan-Erik ;
Tanko, Laszlo B. ;
Colli, Enrico ;
Klarskov, Peter .
BJU INTERNATIONAL, 2012, 110 (11) :1721-1728
[3]   Gonadotropin-releasing hormone (GnRH) and GnRH receptor in bladder cancer epithelia and GnRH effect on bladder cancer cell proliferation [J].
Bahk, Jong Yoon ;
Kim, Myeong Ok ;
Park, Moon Seok ;
Lee, Hae Young ;
Lee, Jeong-Hee ;
Chung, Bong Chul ;
Min, Seung Ki .
UROLOGIA INTERNATIONALIS, 2008, 80 (04) :431-438
[4]   BENIGN PROSTATIC HYPERPLASIA SPECIFIC HEALTH-STATUS MEASURES IN CLINICAL RESEARCH - HOW MUCH CHANGE IN THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX AND THE BENIGN PROSTATIC HYPERPLASIA IMPACT INDEX IS PERCEPTIBLE TO PATIENTS [J].
BARRY, MJ ;
WILLIFORD, WO ;
CHANG, YC ;
MACHI, M ;
JONES, KM ;
WALKERCORKERY, E ;
LEPOR, H .
JOURNAL OF UROLOGY, 1995, 154 (05) :1770-1774
[5]  
Cho Kang Jun, 2011, Int Neurourol J, V15, P152, DOI 10.5213/inj.2011.15.3.152
[6]  
Choi Hoon, 2010, Int Neurourol J, V14, P261, DOI 10.5213/inj.2010.14.4.261
[7]  
Ebara S, 2007, ACTA MED OKAYAMA, V61, P335
[8]  
Frazier A, 2000, RADIOTHER ONCOL S, V55, P77
[9]   The promise of novel androgen receptor antagonists [J].
Gioeli, Daniel G. .
CELL CYCLE, 2010, 9 (03) :440-441
[10]   Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects [J].
Gleave, ME ;
Goldenberg, SL ;
Chin, JL ;
Warner, J ;
Saad, F ;
Klotz, LH ;
Jewett, M ;
Kassabian, V ;
Chetner, M ;
Dupont, C ;
Van Rensselaer, S .
JOURNAL OF UROLOGY, 2001, 166 (02) :500-506